摘要
目的用循证医学的方法分析重组改构人肿瘤坏死因子（rmhTNF）联合常规化疗治疗晚期非小细胞肺癌（NSCLC）的有效性和安全性。方法计算机检索中国Cochrane中心临床对照试验资料数据库、Cochrane临床对照试验数据库、中国生物医学文献数据库（CBM）、中国学术期刊全文数据库（CNKI）、维普中文科技期刊全文数据库（VIP）、万方数据库、美国《医学索引》（MEDLINE）、生物医学与药理学文摘数据库（EMBase）、科学网（webof Science），查找2001年1月至2011年12月发表的有关rmhTNF联合常规化疗治疗晚期NSCLC的随机对照临床试验（RCT），由2名评价者独立进行文献质量评价和资料提取，并进行荟萃分析（Meta分析）结果共纳入5篇文献、421例患者，rmhTNF联合化疗组（试验组）286例，单纯常规化疗组（对照组）135例。Meta分析显示：与单纯化疗相比，联合使用rmhTNF能提高NSCLC患者近期疗效[优势比（OR）=2．87，95％可信区间（95％C1）为（1．78，4．63），P〈0．0001]。患者生存质量评分（KPS）显示，试验组患者用药后KPS评分提高[均数差=8．50，95％CI为（5．29，11．71），P〈0．00001]，且无严重不良反应发生。结论应用rmhTNF联合常规化疗治疗晚期NSCLC有助于提高近期临床疗效，改善患者的一般状况和生活质量，不失为一种安全有效的治疗方法。
Objective To review the effectiveness and safety of the recombination mutant human tumor necrosis factor （rmhTNF）combined with conventional chemotherapy in treatment of terminal non-small cell lung cancer （NSCLC）. Methods Computer retrieval published literatures about the randomly controlled trials （RCT） of rmh-TNF combined with conventional chemotherapy in treatment of terminal NSCLC from January 2001 to December 2011 in The Cochrane Central Register, CBM, CNKI, and VIP Database for Chinese Technical Periodicals, Wanfang, MEDLINE, EMbase and Web of Science were reviewed. Two researchers worked on the quality evaluation and data extraction independently, then they proceeded to Meta analysis. Results Five articles were included, totally there were 421 patients, among them 286 patients in experimental groups were treated by rmhTNF combined with conventional chemotherapy, and 135 patients in control groups were treated by conventional chemotherapy only. The results of the Meta analysis showed that compared with the chemotherapy alone, the combination with rmhTNF could improve NSCLC patients＇ short-term curative effect [ odds ratio （OR） =2.87,95% confidence interval （95%CI） 1.78 to 4.63, P〈0.O0011. The quality of life score （Karnofsky score, KPS） indicated that in the experimental groups, patients＇ KPS score was increased after rmhTNF administration （mean difference = 8.50,95%CI 5.29 to 11.71, P〈0.000 01）, and no obvious adverse reactions were found. Conclusion Using rmhTNF combined with conventional chemotherapy is a safe and effective method for treatment of terminal NSCLC, which can enhance NSCLC patients＇ short-term curative effects and also improve the patients＇ general situation and quality of life.
出处
《中国中西医结合急救杂志》
CAS
北大核心
2012年第5期296-299,共4页
Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care
关键词
重组改构人肿瘤坏死因子
化疗
非小细胞肺癌
系统评价
Recombination mutant human tumor necrosis factor
Chemotherapy
Non-small cell lung cancer
Systematic review
